Factor XIa inhibitors: A review of the patent literature

References

• Raskob GE, Angchaisuksiri P, Blanco AN. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34:2363–2371.
   PubMed Web of Science ®Google Scholar
• Mahan CE, Holdsworth MT, Welch SM, et al. Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost. 2011;106:405–415.
   PubMed Web of Science ®Google Scholar
• Henry BL, Desai UR. Anticoagulants: Drug discovery and development. In: Rotella D, Abraham DJ, editors. Burger’s medicinal chemistry. 7th ed. New York: John Wiley and Sons; 2010. p. 365–408.
   Google Scholar
• Garcia DA1, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e24S–43S.
   PubMed Web of Science ®Google Scholar
• Ageno W1, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S–88S.
   PubMed Web of Science ®Google Scholar
• Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013:464–470.
   PubMed Web of Science ®Google Scholar
• Lee AYY. Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol. 2009;27:4895‒901.
   Web of Science ®Google Scholar
• Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy, 8th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2008;133:844S–86S.
   PubMed Web of Science ®Google Scholar
• Chen Z, Seiffert D, Hawes B. Inhibition of factor XI activity as a promising antithrombotic strategy. Drug Discov Today. 2014;19:1435–1439.
   PubMed Web of Science ®Google Scholar
• Bane CE Jr, Gailani D. Factor XI as a target for antithrombotic therapy. Drug Discov Today. 2014;19:1454–1458.
   PubMed Web of Science ®Google Scholar
• Schumacher WA, Luettgen JM, Quan ML, et al. Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol. 2010;30:388–392.
   PubMed Web of Science ®Google Scholar
• Löwenberg EC, Meijers JC, Monia BP, et al. Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost. 2010;8:2349–2357.
   PubMed Web of Science ®Google Scholar
• He R, Chen D, He S. Factor XI: hemostasis, thrombosis, and antithrombosis. Thromb Res. 2012;129:541–550.
   PubMed Web of Science ®Google Scholar
• Emsley J, McEwan PA, Gailani D. Structure and function of factor XI. Blood. 2010;115:2569–2577.
   PubMed Web of Science ®Google Scholar
• Gailani D, Smith SB. Structural and functional features of factor XI. J Thromb Haemost. 2009;7:75–78.
   PubMed Web of Science ®Google Scholar
• Yang L, Sun MF, Gailani D, et al. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor. Biochemistry. 2009;48:1517–1524.
   PubMed Web of Science ®Google Scholar
• Badellino KO, Walsh PN. Localization of a heparin binding site in the catalytic domain of FXIa. Biochemistry. 2001;40:7569–7580.
   PubMed Web of Science ®Google Scholar
• Mackman N, Tilley RE, Nigel S, et al. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27:1687–1693.
   PubMed Web of Science ®Google Scholar
• Gailani D, Renne´ T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol. 2007;27:2507–2513.
   PubMed Web of Science ®Google Scholar
• Gailani D, Renne´ T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J Thromb Haemost. 2007;5:1106–1112.
   PubMed Web of Science ®Google Scholar
• Gailani D, Lasky NM, Broze GJ Jr. A murine model of factor XI deficiency. Blood Coagul Fibrinolysis. 1997;8:134–44.
   PubMed Web of Science ®Google Scholar
• Wang X, Cheng Q, Xu L, et al. Effects of factor IX or factor XI deficiency on ferric chloride induced carotid artery occlusion in mice. J Thromb Haemost. 2005;3:695–702.
   PubMed Web of Science ®Google Scholar
• Wang X, Smith PL, Hsu MY, et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost. 2006;4:1982–8.
   PubMed Web of Science ®Google Scholar
• Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost. 2002;87:774–776.
   PubMed Web of Science ®Google Scholar
• Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202:271–281.
   PubMed Web of Science ®Google Scholar
• Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006;203:513–518.
   PubMed Web of Science ®Google Scholar
• Müller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139:1143–1156.
   PubMed Web of Science ®Google Scholar
• Jin L, Pandey P, Babine RE, et al. Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors. Acta Crystallogr D Biol Crystallogr. 2005;61:1418–25.
   PubMed Web of Science ®Google Scholar
• Fradera X, Kazemier B, Carswell E, et al. High-resolution crystal structures of factor XIa coagulation factor in complex with nonbasic high-affinity synthetic inhibitors. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012;68:404–408.
   PubMedGoogle Scholar
• Hanessian S, Larsson A, Fex T, et al. Design and synthesis of macrocyclic indoles targeting blood coagulation cascade factor XIa. Bioorg Med Chem Lett. 2010;20:6925–6928.
   PubMed Web of Science ®Google Scholar
• Lin J, Deng H, Jin L, et al. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. J Med Chem. 2006;49:7781–91.
   PubMed Web of Science ®Google Scholar
• Lazarova TI, Jin L, Rynkiewicz M, et al. Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa. Bioorg Med Chem Lett. 2006;16:5022–5027.
   PubMed Web of Science ®Google Scholar
• Schumacher WA, Seiler SE, Steinbacher TE, et al. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol. 2007;570:167–74.
   PubMed Web of Science ®Google Scholar
• Wong PC, Crain EJ, Watson CA, et al. A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J Thromb Thrombolysis. 2011;32:129–37.
   PubMed Web of Science ®Google Scholar
• Buchanan MS, Carroll AR, Wessling D, et al. Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa. J Med Chem. 2008;51:3583–3587.
   PubMed Web of Science ®Google Scholar
• Hangeland JJ, Friends TJ, Rossi KA, et al. Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity. J Med Chem. 2014;57:9915–32.
   PubMed Web of Science ®Google Scholar
• Lin J, Deng H, Jin L, et al., et al. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. J Med Chem. 2006;49:7781–7791.
   PubMed Web of Science ®Google Scholar
• Quan ML, Wong PC, Wang C, et al. Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors. J Med Chem. 2014;57:955‒969.
   Google Scholar
• Bayer Pharma, Germany. Preparation of substituted phenylalanine derivatives as factor XI modulators for treating thrombotic and thromboembolic diseases. WO2015044174A1, WO2015044165A1, WO2015044170A1, WO2015044173A1, WO2015044169A1, WO2015044167A1, WO2015044172A1, WO 2015044163A1; 2015.
   Google Scholar
• Merck Sharp & Dohme, USA. FXIa inhibitors. WO2015164308A1; 2015.
   Google Scholar
• Bristol Myers Squibb Co., USA. Preparation of pyridazine derivatives as factor XIa inhibitors. WO2009114677A1; 2009.
   Google Scholar
• Bristol Myers Squibb Co., USA. Preparation of 5-​membered heterocycles as serine protease inhibitors for treatment of thromboembolic disorders. US20050282805A1; 2005.
   Google Scholar
• Sichuan Haisco Pharmaceutical Co., China. Pyridone or pyrimidone derivatives as coagulation factor XIa inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2015120777A1; 2015.
   Google Scholar
• Merck Sharp & Dohme, USA. Preparation of 2-​oxopyridine compounds as therapeutic Factor XIa inhibitors. WO2014160592A2; 2014.
   Google Scholar
• Merck Sharp & Dohme, USA. Factor XIa inhibitors for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. WO2015123091A1; 2015.
   Google Scholar
• Bayer Pharma, Germany. Preparation of substituted oxopyridine derivatives as factor XIa and plasma kallikrein inhibitors. WO2015063093A1; 2015.
   Google Scholar
• Bayer Pharma, Germany. Preparation of substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders. WO2014154794A1; 2014.
   Google Scholar
• Bayer Pharma, Germany. Substituted oxopyridine derivatives and use thereof as factor XIa​/plasma. WO2015011087A1; 2015.
   Google Scholar
• LegoChem Bioscience Co., S. Korea. Dipeptide derivatives having factor XIa-​inhibiting activities. KR2013131775A; 2013.
   Google Scholar
• Hu Z, Wong PC, Gilligan PJ, et al. Discovery of a potent parenterally administered factor XIa inhibitor with hydroxyquinolin-2(1H)-one as the P2ʹ moiety. ACS Med Chem Lett. 2015;6:590–5.
   PubMed Web of Science ®Google Scholar
• Fjellström O, Akkaya S, Beisel HG, et al. Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design. PLoS One. 2015;10:e0113705.
   Google Scholar
• Suntory Pharmaceutical Research Laboratories, USA. Crystal structure of coagulation factor XIa-inhibitor complexes yield a pharmacophore structure useful for the design of compounds for treatment of thrombosis. WO2004103270A2; 2004.
   Google Scholar
• Suntory Pharmaceutical Research Laboratories, USA. Blood coagulation factor XI inhibitors and methods for treatment of thrombosis. WO 2004089297A2; 2004.
   Google Scholar
• Bristol Myers Squibb Co., USA. Methods of treating thrombosis with reduced risk of increased bleeding times by administration of a small mol. inhibitor of Factor XIa. US20040180855A1; 2004.
   Google Scholar
• Exithera Pharmaceuticals, USA. Preparation of β-lactam derivatives as inhibitors of factor XIa or kallikrein. WO2015120062A2; 2015.
   Google Scholar
• Daiamed, USA. Preparation of substituted azetidinones as inhibitors of tryptase, thrombin, trypsin and Factors Xa, VIIa and XIa. WO2006108039A2; 2006.
   Google Scholar
• Ono Pharmaceutical Co., Japan. Pharmaceutical composition comprising 1,2,4-substituted pyrrolidine derivative as factor XIa inhibitor. JP2015120685A; 2015.
   Google Scholar
• Ono Pharmaceutical Co., Japan. Preparation of 1,2,4-substituted pyrrolidines as factor XIa inhibitors useful in the treatment thromboembolic diseases. WO2013174937A1; 2013.
   Google Scholar
• Merck Sharp & Dohme, USA. Factor XIa inhibitors for treatment of thrombosis, embolisms, hypercoagulability or fibrotic changes. WO2015054087A1; 2015.
   Google Scholar
• Merck Sharp & Dohme, USA. Factor XIa inhibitors for treatment or prevention of thromboses, embolisms, hypercoagulability or fibrotic changes. WO2015047973A1; 2015.
   Google Scholar
• Dainippon Sumitomo Pharma Co., Japan. Preparation of condensed 5-​oxazolidinone derivatives as factor XIa inhibitors useful for oral prodrugs. WO2015107724A1; 2015.
   Google Scholar
• Dainippon Sumitomo Pharma Co., Japan. Preparation of 3-substituted proline derivatives as FXIa inhibitors. JP2015083542A; 2015.
   Google Scholar
• Dainippon Sumitomo Pharma Co., Japan. Preparation of 1-(heteroarylcarbonyl)​proline derivatives as FXIa inhibitors. JP2015013821A; 2015.
   Google Scholar
• Dainippon Sumitomo Pharma Co., Japan. Preparation of 1-(cycloalkylcarbonyl)​proline derivatives having excellent FXIa inhibitory activity. WO2014014050A1; 2014.
   Google Scholar
• Dainippon Sumitomo Pharma Co., Japan. Preparation of 3-substituted proline derivatives as FXIa inhibitors. WO2013118805A1; 2013.
   Google Scholar
• Bristol-Myers Squibb Co., USA. Preparation of azolyl arylpropionamides, arylacrylamides, arylpropynamides, or arylmethylurea analogs as factor XIa inhibitors. WO2008076805A2; 2008.
   Google Scholar
• Ono Pharmaceutical Co., Japan. Pyridinone and pyrimidinone derivatives as factor XIa inhibitors and their preparation and use in the treatment of thromboembolic diseases. WO2013093484A1; 2013.
   Google Scholar
• Bristol-Myers Squibb Co., USA. Preparation of tetrahydroisoquinoline derivatives for use as coagulation factor XIa inhibitors. WO2014160668A1; 2014.
   Google Scholar
• Bristol-Myers Squibb Co., USA. Preparation of guanidine and amine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors. WO2014059214A1; 2014.
   Google Scholar
• Bristol-Myers Squibb Co., USA. Preparation of guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors. WO2014059202A1; 2014.
   Google Scholar
• Bristol-Myers Squibb Co., USA. Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors. WO2013056060A1; 2013.
   Google Scholar
• Bristol-Myers Squibb Co., USA. Preparation of substituted tetrahydroisoquinoline compounds as factor XIa inhibitors. WO2013055984A1, WO 2013056034A1; 2013.
   Google Scholar
• Bristol-Myers Squibb Co., USA. Preparation of tetrahydroquinoline derivatives as inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system. WO2004080971A1; 2004.
   Google Scholar
• Abdel-Magid. Inhibitors of factor XIa and plasma kallikrein may treat thromboembolic disorders and many diabetes complications. ACS Med Chem Lett. 2014;5:286–287.
   PubMedGoogle Scholar
• Bristol-Myers Squibb Co., USA. Macrocycle derivatives as factor XIa inhibitors and their preparation and use for the treatment of thromboembolic and inflammatory diseases. WO2011100402A1; 2011.
   Google Scholar
• Bristol-Myers Squibb Co., USA. Preparation of tetrazolylphenyldiazatricyclooctadecapen​taenylacrylamide derivatives and analogs for use as factor XIa inhibitors. WO 2011100401A1; 2011.
   Google Scholar
• Bristol-Myers Squibb Co., USA. Novel macrocycles as factor XIa inhibitors and their preparation. WO 2013022818A1, WO2013022814A1; 2013.
   Google Scholar
• Bristol-Myers Squibb Co., USA. Preparation of macrocycles condensed with heterocycles as factor IXa inhibitors. WO2015116882A1; 2015.
   Google Scholar
• Bristol-Myers Squibb Co., USA. Dihydropyridones as factor XIa inhibitors and their preparation. WO2014022766A1, WO2014022767A1; 2014.
   Google Scholar
• Bristol-Myers Squibb Co., USA. Preparation of macrocycles with heterocyclic p2ʹ groups as factor XIa inhibitors. WO2015116885 A1, WO2015116886A1; 2015.
   Google Scholar
• Merck Sharp & Dohme Corp., USA. Factor XIa inhibitors for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. WO2015123090A1, WO2015123093A1; 2015.
   Google Scholar
• Virginia Commonwealth University, USA. Preparation of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site. WO2014075045 A1; 2014.
   Google Scholar
• Al-Horani RA, Ponnusamy P, Mehta AY, et al. Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. J Med Chem. 2013;56:867–878.
   PubMed Web of Science ®Google Scholar
• Al-Horani RA, Desai UR. Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides. J Med Chem. 2014;57:4805–18.
   PubMed Web of Science ®Google Scholar
• Patel NJ, Karuturi R, Al-Horani RA, et al. Synthetic, non-saccharide, glycosaminoglycan mimetics selectively target colon cancer stem cells. ACS Chem Biol. 2014;9:1826–1833.
   PubMed Web of Science ®Google Scholar
• Al-Horani RA, Gailani D, Desai UR. Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants. Thromb Res. 2015;136:379–387.
   PubMed Web of Science ®Google Scholar
• Karuturi R, Al-Horani RA, Mehta SC, et al. Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site. J Med Chem. 2013;56:2415–2428.
   PubMed Web of Science ®Google Scholar
• National University of Singapore, Singapore. Use of BF01 peptide inhibiting Factor XIa for use as anticoagulant with minimal side effects of bleeding. WO2015002611A1; 2015.
   Google Scholar
• Chen W, Carvalho LP, Chan MY, et al. Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity. J Thromb Haemost. 2015;13:248–61.
   PubMed Web of Science ®Google Scholar
• Ma D, Mizurini DM, Assumpção TC, et al. Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo. Blood. 2013;122:4094–4106.
   PubMed Web of Science ®Google Scholar
• Li D, He Q, Kang T, et al, Identification of an anticoagulant peptide that inhibits both fXIa and fVIIa/tissue factor from the blood-feeding nematode Ancylostoma caninum. Biochem Biophys Res Commun. 2010;392:155–159.
   PubMed Web of Science ®Google Scholar
• GuangDong Medical College, China. Anticoagulant polypeptide and its application as selective inhibitor of coagulation factor XIa. WO2012116663A1; 2012, CN102241734A; 2011.
   Google Scholar
• Decrem Y, Rath G, Blasioli V, et al., et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med. 2009;206:2381–2395.
   PubMed Web of Science ®Google Scholar
• Universite Libre de Bruxelles, Belgium. Anticoagulant polypeptide from salivary glands of Ixodes ricinus. WO2009141382A1, EP2123670A1; 2009.
   Google Scholar
• University of Georgia Research Foundation, Inc., USA; U.S. Dept of Health and Human Services. An anticoagulant proteinase inhibitor from the salivary glands of Simulium vittatum and its therapeutic uses. WO2012162611A1; 2012.
   Google Scholar
• Tsujimoto H, Kotsyfakis M, Francischetti IM, et al. Simukunin from the salivary glands of the black fly Simulium vittatum inhibits enzymes that regulate clotting and inflammatory responses. PLoS One. 2012;7:e29964.
   PubMedGoogle Scholar
• Bayer Healthcare A.-G., Germany. Inhibitory domains of human Kunitz-type protease inhibitors and their manufacture for therapeutic use. WO2009030464A2; 2009.
   Google Scholar
• University of California, USA. Ecotin variants as inhibitors or activators of serine proteinases. WO2000061782A1, WO2000061634A2; 2000.
   Google Scholar
• Corvas International, USA. Ecotin as a factor Xa, XIa, and XIIa inhibitor. US5585259A; 1996.
   Google Scholar
• Genentech, USA. Kunitz domain inhibitor proteins derived from Alzheimer’s amyloid β-protein precursor inhibitor. WO9523860A2; 1995.
   Google Scholar
• Lippi G, Harenberg J, Mattiuzzi C, et al. Next generation antithrombotic therapy: focus on antisense therapy against coagulation factor XI. Semin Thromb Hemost. 2015;41:255–262.
   PubMed Web of Science ®Google Scholar
• DeVos SL, Miller TM. Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics. 2013;10:486–497.
   PubMed Web of Science ®Google Scholar
• ISIS Pharmaceuticals, USA. Antisense nucleic acids inhibiting clotting factor XI biosynthesis in the treatment of cardiovascular disorders. WO2010045509A2; 2010.
   Google Scholar
• ISIS Pharmaceuticals, USA. Antisense inhibitors of blood coagulation factor XI gene expression as modulators of inflammation. WO 2010121074A1; 2010.
   Google Scholar
• ISIS Pharmaceuticals, USA. Administration of human Factor XI modified antisense oligonucleotides that decrease Factor XI activity to treat or prevent thromboembolic or inflammatory disorders. WO2013070771A1; 2013.
   Google Scholar
• Zhang H, Löwenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 2010;116:4684–4692.
   PubMed Web of Science ®Google Scholar
• van Montfoort ML, Kuijpers MJ, Knaup VL, et al. Factor XI regulates pathological thrombus formation on acutely ruptured atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2014;34:1668–1673.
   PubMed Web of Science ®Google Scholar
• Younis HS, Crosby J, Huh JI, et al. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood. 2012;119:2401–2408.
   PubMed Web of Science ®Google Scholar
• Crosby JR1, Marzec U, Revenko AS, et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol. 2013;33:1670–1678.
   PubMed Web of Science ®Google Scholar
• Yau JW, Liao P, Fredenburgh JC, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014;123:2102–2107.
   PubMed Web of Science ®Google Scholar
• Que Liu ED, Claudette B, Shuting X, et al. Isis-fxirx, a novel and specific antisense inhibitor of factor xi, significantly reduces fxi antigen and activity and increases APTT without causing bleeding in healthy volunteers. Blood. 2011;118:209.
   Google Scholar
• Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372:232–40 .
   PubMed Web of Science ®Google Scholar
• Bayer Pharma, Germany. Preparation of human antibodies capable of binding to the coagulation factor XI and​/or its activated form factor XIa for treatment of thrombosis. WO2013167669A1; 2013.
   Google Scholar
• Yamashita A, Nishihira K, Kitazawa T, et al. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. J Thromb Haemost. 2006;4:1496–1501.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Yamashita A, Moriguchi-Goto S, et al. Inhibition of factor XI reduces thrombus formation in rabbit jugular vein under endothelial denudation and/or blood stasis. Thromb Res. 2010;125:464–470.
   PubMed Web of Science ®Google Scholar
• Oregon Health & Science University and Vanderbilt University, USA. Anti-​human factor XI monoclonal antibodies for treating thrombosis, metastatic cancer and acute inflammatory reaction. WO2009067660A2; 2009.
   Google Scholar
• Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood. 2009;113:936–44.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010;116:3981–3989.
   PubMed Web of Science ®Google Scholar
• Leung PY, Hurst S, Berny-Lang MA, et al. Inhibition of factor XII-mediated activation of factor XI provides protection against experimental acute ischemic stroke in mice. Transl Stroke Res. 2012;3:381–9.
   PubMed Web of Science ®Google Scholar
• Tucker EI, Verbout NG, Leung PY, et al. Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood. 2012;119:4762–4768.
   PubMed Web of Science ®Google Scholar
• Luo D, Szaba FM, Kummer LW, et al. Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis. Infect Immun. 2012;80:91–99.
   PubMed Web of Science ®Google Scholar
• van Montfoort ML, Knaup VL, Marquart JA, et al. Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model. Thromb Haemost. 2013;110:1065–1073.
   PubMed Web of Science ®Google Scholar
• Gruber A, Hanson SR. Factor XI-dependence of surface- and tissue factor initiated thrombus propagation in primates. Blood. 2003;102:953–955.
   PubMed Web of Science ®Google Scholar
• Szalony JA, Suleymanov OD, Salyers AK, et al. Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time. Thromb Res. 2003;112:167–174.
   PubMed Web of Science ®Google Scholar
• Suleymanov OD, Szalony JA, Salyers AK, et al. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: Comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J Pharmacol Exp Ther. 2003;306:1115–1121.
   PubMed Web of Science ®Google Scholar